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Thankstotheprogressinoncostatic treatments,young womenaﬀected bycancer have afairlygoodchance ofsurvivingthedisease
and leading a normal post-cancer life. Quite often, however, polychemiotherapy and/or radiotherapy can induce ovarian damage
and signiﬁcantly reduce the content of follicles and oocytes inside the ovary, thus predisposing the patient to menstrual disorders,
infertility, and precocious menopause. Several techniques have been proposed to preserve fertility in these patients; among them
oocyte collection and cryopreservation prior to the oncostatic treatment has been widely applied in the last decade. The proper
indications, the permitting conditions, the available hormonal stimulation protocols, as well as the eﬀectiveness and limits of this
option will be discussed herein, with a comprehensive and up-to-date review of the two techniques commonly used to cryostore
oocytes, the slow-freezing technique and the vitriﬁcation technique.
1.Introduction
During the past decade, fertility preservation has become an
important issue in cancer patients’ management. Survival
rates after malignancy treatment have improved markedly,
especially for young women aﬀected by melanoma, onco-
haematological diseases, and breast cancer, leading to the
generation of long-term cancer survivors [1, 2]; nonetheless,
this population is quite frequently aﬀected by iatrogenic
infertility and/or premature ovarian insuﬃciency (POI) [3].
Recent studies, in fact, showed that abdominal radiotherapy
may lead to ovarian damage in a dose-dependent fashion;
similarly, total body irradiation may result in POI in
about 97% of cases [4]. Chemotherapy regimens, especially
those involving alkylating agents, may cause acute loss of
follicles within the ovary, leading to hormone deﬁciency and
permanent infertility [5]. Psychological distress induced by
the loss of reproductive perspective as well as factors related
to a premature menopause (osteoporosis, cardiovascular
diseases, depression, etc.) may dramatically aﬀect survived
women’squalityoflife.Althoughdiseaseremissionobviously
remainstheﬁrstgoalofcancertreatment,patient’sawareness
toward safeguarding future fertility is increasing [6].
Manyapproacheshavebeenconsideredtopreservefertil-
ity and avoid POI. Embryo cryostorage has been considered
for years the only valid option, albeit this procedure is appli-
cable only to stable couples and not to singles, and still raises
a lot of ethical, legal, and practical concerns. Ovarian cortex
ablation and cryostorage, with subsequent autografting, is
the only strategy which can be proposed to prepubertal girls,
though it is still considered an experimental approach with
limited results.
Nowadays, oocyte cryostorage is considered an impor-
tant tool for fertility preservation worldwide, as no surgery
is required and minimally invasive ovarian stimulation
protocols are available. Moreover, storing oocytes implies
no concerns regarding possible cancer cells contamination,
a problem that aﬀects ovarian cortex retransplantation strat-
egy [7]. As a result of oocyte cryostorage and in vitro fertil-
ization (IVF), over 2000 babies were born in nononcological,
routine IVF patients.
2. History of Oocyte Cryostorage
Since oocyte cryostorage was introduced in the mid 1980s,
general interest rose around the possibility of increasing2 Obstetrics and Gynecology International
pregnancy rates using frozen eggs, overcoming the ethical
and legal concerns related to embryo freezing.
Since the very beginning oocyte freezing was quite prob-
lematic, with survival and fertility rates below 50%, and
pregnancy rates as low as 1-2% [8–10]. Chen and Van Uem
et al. reported the ﬁrst pregnancies obtained after oocyte
freezing/thawing, raising many expectations in scientiﬁc
community [11, 12]. Unfortunately, many other attempts
failed to reach the same result [13–15]: oocyte freezing
strategywasdramaticallylesseﬀectivethanzygoteorembryo
cryopreservation. Before intracytoplasmatic sperm injection
(ICSI) was introduced in most IVF laboratories, the prema-
ture release of cortical granules by the frozen oocyte with
the consequent irreversible thickening of the zona pellucida
was able to halt sperm penetration and impair fertilization
[16, 17].
Cryobiologists encountered several problems in freezing
oocytes, including ice crystal formation, osmotic stress, and
cryoprotectant agents (CPAs) toxicity [8, 18, 19]. Compared
to other mammalian cells, human mature oocytes are
constituted by a very high amount of water and have a
small surface-to-volume ratio, which strongly aﬀects cells
dehydration that is essential for survival after thawing. Zona
pellucida cracking, mitochondria shrinkage, and microﬁla-
ments alteration were also addressed as cryostorage-induced
injuries on the human oocyte [20]. Moreover, meiotic
spindle (MS) disassembly induced by cooling was clearly
shown after the introduction of polarized light microscopy
analysis. Many authors reported that when oocytes are
exposed to low temperatures, the MS disappears from their
oocytes, and reappears as a consequence of repolymerization
after a few hours of incubation at thawing temperature
[21, 22]. The survival of an oocyte after warming can
be assessed when a bright cytoplasm surrounded by an
intact zona pellucida is observed; anyway, chilling female
gametes to subzero temperatures provides damages to their
ultrastructure,asobservedbyseveralauthorswhoperformed
electron microscope analysis: the main consequences of
freezing/thawing procedures involve organelle displacement,
mitochondrial disruption, vacuolization of the ooplasm,
and loss of spindle polarity predisposing to an altered
chromosomal alignment [23–25].
Cryobiology aims at minimizing these harmful eﬀects
on the human oocyte, and by now, two well-established
laboratory protocols have been proposed and are widely
diﬀused in the clinical practice: the slow freezing protocol
and the vitriﬁcation procedure.
3. Candidatesfor Oocyte Cryopreservation
Fertility preservation should be discussed with all young
women at high risk of POI. The most common cause of POI
are ovarotoxic anticancer therapies, and cancer patients are
by far the main candidates to fertility preservation. However,
benign diseases like some genetic syndromes (Turner’s
syndrome, X-fragile carrier condition, etc.), ovarian diseases
(severe endometriosis or ovarian cysts requiring ablative
surgery), or autoimmune disorders requiring immunosup-
pressive therapy may determine POI as well.
Cancer in women in reproductive age is an increasing
problem. The American Cancer Society estimates that 1/47
women will develop a cancer before the age of 39 (American
Cancer Society, Inc., Surveillance Research 2011). Every year,
about 200.000 new cases of breast cancer are diagnosed in
USA, 15% of which occur in women under the age of 45.
Most of these patients will receive adjuvant chemotherapy
with alkylating drugs 4 to 6 weeks after surgery, developing
a high risk of POI [26] (National Institute of Health Con-
sensus Development Panel, 2001). Many breast cancer cases,
however, are hormone-sensitive, and appropriate ovarian
stimulation regimens are needed to keep low circulating
estrogen levels while stimulating the ovary to cryostore
oocytes [27–30]. Haematological malignancies such as lym-
phoma and leukemia show now quite good survival rates,
and the attention is shifting toward the prevention of side
eﬀects like infertility [31].
Even nonneoplastic diseases (autoimmune disorders or
benign haematologic diseases being treated with chemo- or
radiotherapy) should routinely implicate the oﬀer of oocyte
cryopreservation [32, 33].
The selection of candidates for fertility preservation is
crucial in order to oﬀer the best suitable technique for
each patient. Oocyte cryopreservation is probably the best
technique to preserve fertility of women without an estab-
lished partner or wishing to avoid ethical and legal problems
associated with embryo cryostorage. When feasible, oocyte
cryostorage may be preferable to ovarian tissue freezing
because it does not require surgery and has already resulted
in many live births [9].
The most important limiting factor for oocyte cryop-
reservation is age: storing oocytes in women after 40 years
of age will probably result in a very poor chance to get
a pregnancy in the future. Indeed, patients with a poor
ovarian reserve have to be screened carefully, since they may
not beneﬁt from the treatment. Ovarian reserve assessment
is crucial for patients requiring oocyte cryostorage: besides
age, the antral follicle count and hormonal parameters such
as FSH and anti-Mullerian hormone (AMH) have to be
carefully considered. On the other side, oocyte cryopreserva-
tion is unavailable for prepubertal girls because the ovarian
stimulation used to obtain oocytes needs the full maturity of
the hypothalamus-pituitary-ovarian axis.
Another limiting issue is the timing of the procedure:
oocyte cryopreservation requires an average of 12 days for
ovarian stimulation and ovum pickup (OPU) to occur [34].
Women starting oncostatic therapy in a very short time from
diagnosis or having already started chemotherapy may not
beneﬁt from oocyte cryostorage.
Oocytecryopreservation implies acontrolledovarianhy-
perstimulation with exogenous gonadotropins that leads to
largelysupraphysiologicallevelsof serumestradiol. Typeand
stage of the neoplastic disease and the patient’s overall health
inﬂuencethefeasibilityofanovarianstimulation,andstimu-
lation protocols must be individualized for every woman. In
this perspective, the use of conventional ovarian stimulation
protocolsispossibleonlyinwomenwithestrogen-insensitive
tumours, while hormone-responsive diseases require appro-
priate regimens [35].Obstetrics and Gynecology International 3
4.OvarianStimulationProtocol
Each protocol that aims at obtaining oocytes for cryostorage
should be (i) safe, with limited risk of stimulating the growth
of a pre-existing neoplasia, (ii) fast, with very limited delay
in starting cancer therapy, (iii) eﬀective, with good chances
of oocyte retrieval.
Ovarian stimulation requires approximately 10–14 days
to achieve mature oocytes at OPU. In case of estrogen-
sensitive diseases, the protocol with letrozole (5mg/day
from the second day of menstrual cycle for 5–7 days)
plus gonadotropins (150–300IU of recombinant FSH) and
GnRH-antagonists [30] is one of the most recommendable:
this regimen allows an acceptable oocyte yield and keeps
the circulating estradiol levels rather low [36], a GnRH-
agonist may be used to trigger the follicle ﬁnal maturation,
minimizing the risk of ovarian hyperstimulation syndrome
(OHSS); moreover, letrozole or GnRH-antagonist can be
readministered from the day of OPU until blood estradiol
concentration falls below 50pg/mL. In case of shortage of
time, alternative regimens include to start stimulation in
the luteal phase. Some women, in fact, need an urgent
cancer treatment and cannot delay the beginning of the
oncostatic therapies until the onset of menstruation; in this
case,aGnRH-antagonistisadministeredtoinduceanabrupt
luteolysis and then gonadotropins are started [37]. The egg
retrieval rate is similar to the one observed using longer,
conventional stimulation regimens.
A growing literature showing encouraging results of
oocyte in vitro maturation (IVM) followed by vitriﬁcation
for cryostorage is now available [38, 39]. This option
consists in the possibility to retrieve immature oocytes from
unstimulated preantral follicles, which are arrested in the
prophase of the ﬁrst meiotic division. Immature oocyte
retrieval followed by in vitro maturation (IVM) resulted in
several live births [40] and it is claimed that live births could
be achieved combining oocyte IVM and vitriﬁcation. This
technique is safe and theorically eﬀective for all oncological
patients, as no hormonal stimulation is needed, and it can be
performed with no time restrictions [39]. The eﬀectiveness
of the procedure appears to be higher when immature
oocytes are ﬁrst matured in vitro a n dt h e nf r o z e n[ 41].
The potential of oocyte maturation is, in fact, reduced after
vitriﬁcation [42, 43].
Overall, some data suggest that immature oocytes could
be less sensible to cryodamage than mature oocytes because
their nuclear apparatus is still not fully developed, and after
thawing, they can be matured in vitro to metaphase II
[56, 57]. Cryopreservation of immature oocytes should be
considered in oncological patients who cannot undergo hor-
monal stimulation with high peak estradiol concentrations,
for example, patients with breast cancer [58].
5.Slow FreezingMethod
The slow freezing/rapid thawing method was the ﬁrst cryos-
torage protocol adopted for oocytes in IVF laboratories. It
was originally introduced with the aim to preserve super-
numeraryembryosobtainedfromassistedreproductionpro-
cedures [59, 60].
Oocyte freezing was initially a damping technique: rates
ofsurvivalandcleavageafterthawingweresigniﬁcantlylower
than those obtained using zygote or cleavage stage embryos.
The major burden of mammalian egg cryopreservation was
foundto bemembranepermeabilitytocryoprotectants: after
fertilization, in the zygote and in the cleavage-stage embryo,
water permeability kinetics change, rendering the cells more
prone to freezing [61].
T h eo r i g i n a lp r o t o c o li n t r o d u c e df o rm o u s ee m b ry oc ry -
opreservation was slightly modiﬁed and adapted to human
cells [62]. Small permeating molecules, like dimethyl-
sulfoxide (DMSO) or propandiol (PROH), were adopted to
allow water substitution in the intracellular compartment
and were found to be useful to avoid ice crystal forma-
tion within the oocyte’s cytoplasm. Sucrose-supplemented
media were eﬀective in reducing the shrinking/swelling
phenomenon occurring when osmotic imbalance between
the intracellular compartment and the extracellular envi-
ronment is generated. Some authors [63] observed that
increasing sucrose concentration from 0.1 to 0.2M increased
oocytesurvivalandfertilizationafterthawing;furtherraising
sucrose concentration up to 0.3M yielded even better results
[64]. Sodium replacement with choline in the cryopreserva-
tion medium also obtained satisfactory results [65, 66].
Another crucial point of the oocyte freezing technique
is the rate of freezing, which has to be performed under
strictly controlled conditions: room temperature, as well
as equilibration temperature of cryopreservation media, is
able to interfere with membrane permeability to cryopro-
tectants, possibly aﬀecting the oocyte survival chance [19].
Moreover, since slow freezing technique slowly dehydrates
oocyte cytoplasm, a programmable freezer is required in the
laboratory. The cooling rate must reach, starting from room
temperature (20◦C), a temperature of −7/8◦C with a speed
of −2◦C/min. In order to prevent spontaneous ice crystal
formation, at this stage the operator must perform manual
seeding by touching the device where oocytes have been
previously loaded (usually a plastic straw) with a nitrogen-
cooled object. Subsequently, samples are cooled to −30◦C
at a speed rate of −0,3◦C/min and then deﬁnitively frozen
to −150◦C at a speed rate of −50◦C/min. Diﬀerently, the
warming rate must be very rapid in order to prevent the
recrystallization of intracellular water.
The slow freezing protocol has been considered the
gold standard technique for oocyte cryopreservation for
years; it is a well-established procedure with survival rates
usually as high as 60–80% (Table 1)[ 45, 47, 48, 67, 68].
Nevertheless, some authors emphasized the detrimental
eﬀects of high sucrose concentration on oocyte cytoplasm
organelles and proposed alternative freezing techniques and
timing schedules [23, 52, 69].
Clinical reports on slow freezing show a pregnancy rate
ranging between 13 and 20% (pregnancy/embryo transfer)
(Table 1) and implantation rates still low in comparison
to those observed in fresh cycles [44]. Grifo and Noyes
compared slow freezing to vitriﬁcation on sibling oocytes,
showing similar results in terms of survival, but higher4 Obstetrics and Gynecology International
Table 1: Results from diﬀerent oocyte cryopreservation protocols: slow freezing (high-sucrose concentration) and vitriﬁcation.
Vitriﬁcation
(VIT)
Slow freezing
(SF) Survival Fertilization Pregnancy Miscarriage Egg donation
program
Chen et al., 2005 [44] — Yes 75% (119) 67% (80) 33% (7) 0% Partially
Li et al., 2005 [45] — Yes 90% (73/81) 82% (60/73) 47% (7/15) 28% (2/7) Partially
Kuwayama et al., 2005 [46] Yes — 91% (58/64) 81% (52/64) 41% (12/29) 17% (2/12) No
Borini et al., 2006 [47]— Y e s43,4%
(306/705)
51,6%
(158/306) 19,2% (14/73) 28,6% (4/14) No
Barritt et al., 2007 [48] — Yes 86,1% (68/79) 89,7% (61/68) 75% (3/4) NS Yes
Lucena et al., 2006 [49] Yes — 96,7% (143) 87,2% (105) 56,5% (13) NS Yes
Antinori et al., 2007 [50]Y e s — 99,4%
(328/330)
92,9%
(305/328) 32,5% (39/120) 20,5% (8/39) No
Cobo et al., 2008 [51]Y e s—96,9%
(224/231)
76,3%
(171/224) 65,2% (15/23) 20% (3/15) Yes
Parmegiani et al., 2008 [52]— Y e s 75,1%
(328/437) 80% (227/328) 19% (16/83) 31,2% (5/16) No
Cao et al., 2009 [42]
Yes Yes
SF 61%
(75/123)
SF 61,3%
(46/75) ND ND No
VIT 91,8%
(268/292)
VIT 67,9%
(182/268) ND ND No
Smith et al., 2010 [53]
Yes Yes
SF 65%
(155/238)
SF 67%
(104/155) SF 13% (4/30) SF 25% (1/4) No
VIT 75%
(260/349)
VIT 77%
(200/260)
VIT 38%
(18/48)
VIT 18%
(4/18) No
Rienzi et al., 2010 [54] Yes — 97% (120/124) 79,2% (95/120) 30,8% (15/39) 20% (3/15) No
Cobo et al., 2010 [55] Yes — 92,5% (3039) 73,3% (NS) 55,4% (148) NS Yes
NS = Data not reported.
ND = Data not calculated, not a study endpoint.
fertilization and blastocyst formation rates using the former
[67].
In standard IVF procedures, cryopreserving oocytes
combines the chances to achieve a pregnancy by both fresh
and thawing cycles, thus yielding a rather high cumulative
pregnancy rate [47].
6.VitriﬁcationMethod
Early studies on oocyte vitriﬁcation were performed at the
end of 1980s, when the ﬁrst attempts on mouse or hamster
eggs were reported [70, 71]. The introduction of oocyte
vitriﬁcation in human IVF is a relatively recent phenomenon
[46, 54, 72].
The scientiﬁc basis of vitriﬁcation consists in the ultrara-
pid freezing of cells, whose intra- and extracellular aqueous
environment turns into a glassy-like state. Vitriﬁcation
combines two diﬀerent biophysical processes: a preliminary
equilibration step, in which oocytes are exposed to low
concentrations of cryoprotectants to allow water outﬂow,
and a subsequent vitriﬁcation phase in which cells undergo
a high osmotic gradient that completes cells dehydration.
Under these conditions, oocytes can be directly merged
into liquid nitrogen and then stored. Similarly, warming of
oocytes must be rapid in order to avoid recrystallization of
water.
The cryoprotectants used during vitriﬁcation are the
same employed for slow freezing, but they are three-to-four-
folds more concentrated in vitriﬁcaton than in slow freezing.
DMSO, PROH, and ethylene glycol (EG) (5-6M) as well as
sucrose (1M) are currently used, though their toxicity is still
under evaluation [73].
Appropriate carriers for freezing oocytes are also very
important. Successful vitriﬁcation occurs when samples are
loaded in a minimal ﬂuid volume and then frozen/thawed
at an extremely fast rate (1500–2000◦C/min). Open systems
guarantee direct contact with liquid nitrogen [74, 75]: open-
pulled straws, cryo-tops and cryo-loops, cryo-leafs, electron
microscopy grids, and many other devices were tested in
the last years [39, 46, 76, 77]. All open systems raise some
concerns about the possible viral contamination of stored
material, either from nitrogen or from cross-contamination
among samples [73]: strategies to avoid this risk include
the formulation of high-security closed devices, exposure to
nitrogen vapors, and nitrogen ultraviolet (UV) sterilization
[55, 78].
Although no cross-contamination between liquid nitro-
gen and stored oocytes has been signalled to date, closed
systems may provide the safer and probably most eﬀective
vitriﬁcation procedure. In particular, many carriers have
been approved by FDA in the last years, and several
of them are now commercially available: Cryotip (Irvine
Scientiﬁc, CA, USA), high-security vitriﬁcation (HSV) strawObstetrics and Gynecology International 5
(Cryo BioSystem, Paris, France), VitriSafe (VitriMed, Aus-
tria), Cryopette (Origio, Denmark), and Rapid-i (Vitrolife
Sweden AB) [79]. DNA integrity assessed on warmed mouse
oocytes is comparable in open versus closed vitriﬁcation
systems; anyway, there is still an ongoing debate whether
closed or open vitriﬁcation carriers provide the best results
in terms of fertilization and cleavage rates [80]. On the other
hand, there is wide agreement in considering vitriﬁcation an
operator-dependent procedure.
Oocyte survival after vitriﬁcation reaches 90% in several
reports (Table 1)[ 38, 42, 46, 49, 50, 54, 81]. Oocyte quality
seems to be poorly aﬀected by chilling injury: spindle
repolymerization occurs within one hour after warming,
suggesting that the ultrastructure of these gametes is better
preserved by vitriﬁcation rather than slow freezing [82];
moreover, the metabolomic proﬁling of vitriﬁed oocytes was
found to be comparable to the one of fresh eggs [83, 84].
Data on the clinical use of vitriﬁed eggs in routine
IVF show that pregnancy rates can be comparable to
those achieved with fresh oocytes (Table 1)[ 9, 54, 85].
Studies aimed to compare vitriﬁcation and slow freezing
reported implantation and pregnancy rates trendly higher
with vitriﬁcation, although the number of observed cases
overall is still too low to draw ﬁnal conclusions [42, 51, 53,
81, 86].
7. Conclusions
Cryostoring oocytes is an eﬀective method to preserve fertil-
ity in postpubertal young women at risk of POI. In the last
years, signiﬁcant improvements in the clinical eﬀectiveness
of oocyte freezing/thawing techniques have been achieved
using both slow freezing method and vitriﬁcation. The
available trials comparing these two diﬀerent approaches are
still insuﬃcient to establish the superiority of one over the
other, but the growing interest of scientist and the increasing
awareness of women about the possibility of storing oocytes
will likely lead to the development of an optimal protocol for
oocyte storage in the next few years.
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